

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

pKK-TEV-ProteinA

RRID:Addgene_105788

Type: Plasmid

Proper Citation

RRID:Addgene_105788

Plasmid Information

URL: <http://www.addgene.org/105788>

Proper Citation: RRID:Addgene_105788

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:29590189](https://pubmed.ncbi.nlm.nih.gov/29590189/)

Vector Backbone Description: Backbone Marker:Invitrogen; Vector Backbone:pcDNA5/FRT/TO; Vector Types:Mammalian Expression, Flp-In competent; Bacterial Resistance:Ampicillin

Comments: This vector is a member of the pKK vector family. Its cloning site was optimized for the SLIC approach, however, a traditional restriction and ligation based approach is also possible (see Szczesny RJ et al. for detailed protocols; bioRxiv, doi: <https://doi.org/10.1101/160101>). This vector is a derivate of the pcDNA5/FRT/TO plasmid (Invitrogen) and is suitable for stable cell line generation using the Flp-In system. Transcription of the gene of interest is driven by a tetracycline responsive CMV promoter. A given coding sequence can be cloned into all pKK vectors using just three universal PCR primers and a ligation-independent DNA cloning method. Protein A of Staphylococcus aureus binds to IgG of different origin which can be used for affinity purification or antibody-based detection. Protein A (i.e. two IgG-binding domains of protein A) is often used for tandem affinity purification, in which a protein of interest is expressed in fusion with two different tags (for example Protein A-calmodulin binding peptide) (PMID: 3507693, 10504710). In this vector only Protein A is encoded.

Plasmid Name: pKK-TEV-ProteinA

Record Creation Time: 20220422T221513+0000

Record Last Update: 20260808T080345+0000

Ratings and Alerts

No rating or validation information has been found for pKK-TEV-ProteinA.

No alerts have been found for pKK-TEV-ProteinA.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Arakawa H, et al. (2025) IgAim: cell surface Ig-aimed immune memory erasers for the therapy of autoimmune diseases and B leukemia. NAR molecular medicine, 2(2), ugaf016.